Other
Fear
0
Pipeline Programs↗
5
Active Trials↗
2
Companies Involved↗
Fear is an early-stage landscape with 0 programs across 2 companies. The most active players are Sibel Akgül Kartal, Universite de Picardie Jules Verne.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
11
clinical trials
Not yet recruiting3 · 27%
Completed3 · 27%
Recruiting2 · 18%
Withdrawn2 · 18%
Terminated1 · 9%
Clinical Trials
Trial Activity
11 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)